SCHEMBL3334412

SCHEMBL3334412

Cc1ccc(-n2c(=O)[nH]c3c(C(N)=O)nc(-c4ncc[nH]4)nc32)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 10/20 0.66
KDM4E B2RXH2 6/20 0.64
HSD17B10 Q99714 4/20 0.64
HPGD P15428 3/20 0.64
ALDH1A1 P00352 2/20 0.64
USP2 O75604 2/20 0.64
MAPT P10636 1/20 0.64
PKM P14618 1/20 0.64
ALOX15 P16050 1/20 0.64
XBP1 P17861 1/20 0.64
KMT2A Q03164 5/20 0.61
MEN1 O00255 3/20 0.61
GAA P10253 3/20 0.58
MAPK1 P28482 1/20 0.58
LMNA P02545 2/20 0.54
RXFP1 Q9HBX9 2/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 2/20 0.51
TP53 P04637 1/20 0.51
PIK3CD O00329 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11940597 0.82 CSNK2A1 (0.79) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL11939089 0.82 CSNK2A1 (0.67) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3333973 0.81 CSNK2A1 (0.84) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3334609 0.80 KDM4E (0.67) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3329830 0.79 KDM4E (0.64) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3334350 0.79 CSNK2A1 (0.74) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3335629 0.79 CSNK2A1 (0.70) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL12288530 0.78 CSNK2A1 (0.68) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3333529 0.78 KMT2A (0.81) CSNK2A1KDM4EHSD17B10HPGDALDH1A1
SCHEMBL3333345 0.77 CSNK2A1 (0.64) CSNK2A1KDM4EHSD17B10HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF M.D. ANDERSON CANCER CENTER (US) 2012-11-29 US disclosed
US-8268809-B2 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof EMORY UNIVERSITY (US) 2012-09-18 US disclosed
US-8268809-B2 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof EMORY UNIVERSITY (US) 2012-09-18 US disclosed
EP-2471529-A2 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof Emory University (US) 2012-07-04 EP disclosed
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof EMORY UNIVERSITY (US) 2010-09-30 US disclosed
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof EMORY UNIVERSITY (US) 2010-09-30 US disclosed
US-20100144738-A1 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2010-06-10 US disclosed
US-20100144738-A1 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2010-06-10 US disclosed
US-20100144738-A1 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2010-06-10 US disclosed
WO-2008030744-A2 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-03-13 WO disclosed
WO-2008030744-A2 INHIBITORS OF C-MET AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof MAP3K1, MAP3K2, MAP3K6 CSNK2A1 402/4885KDM4E 1924/4885HSD17B10 4401/4885
US-20100144738-A1 INHIBITORS OF C-MET AND USES THEREOF MET, HGF, HGFAC CSNK2A1 629/4885KDM4E 1415/4885HSD17B10 3770/4885
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF MAP3K1, MAP3K2, MAP3K6 CSNK2A1 402/4885KDM4E 1924/4885HSD17B10 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.